LXRX

Lexicon Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05

Figures on this page computed 2026-11-08 12:48 UTC

Last close

1.48USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-05

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-06
The filing itself
-101.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
-136.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
0.58Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.13 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.75x

0.55x

0.60x

0.53x

0.31x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales0.75x
Its own average over 10 years, 66.3M.
Profit0.55x
Its own average over 10 years, -92.1M.
Free cash flow0.60x
Its own average over 10 years, -112.8M.
Debt0.53x
Its own average over 10 years, 118.1M.
Price0.31x
Its own average over 11 years, 5. Market data, 2026-11-04

Price is furthest from its own average, at 0.31 times.

Sales is 0.75 times its own 10-year average; Profit is 0.55 times its own 10-year average; Free cash flow is 0.60 times its own 10-year average; Debt is 0.53 times its own 10-year average; Price is 0.31 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales against its own 10-year average0.75
Source
filed
Statement
income
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
The filing itself
Profit against its own 10-year average0.55
Source
filed
Statement
income
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
The filing itself
Free cash flow against its own 10-year average0.60
Source
filed
Statement
income
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
The filing itself
Debt against its own 10-year average0.53
Source
filed
Statement
income
Fiscal year
2025
Accession
0001062822-26-000050
Reported in
USD
The filing itself
Price against its own 11-year average0.31Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD